Tesamorelin Side Effects: What the Trials Report

This page reads the current Egrifta prescribing information so you do not have to. It lists every adverse reaction the 26-week trials recorded, sorts them into mild and urgent, and explains what the label tells prescribers to watch. Tesamorelin at PeRx Explore PeRxTesamorelinMetabolic Optimization PeptideView peptide is prescribed by a licensed provider after a health screening, with a check-in before each renewal. For the molecule itself, its history and its evidence, start with the complete tesamorelin guide Read nextTesamorelin Peptide: Benefits, Dosage & Visceral FatMost peptides in the compounding space have animal studies and early clinical signals. Tesamorelin has two Phase 3 randomized controlled trials, 816 patients, CT-measured visceral fat data, and an FDA approval. It is a synthetic analog of growth hormone-releasing hormone that triggers your pituitary to produce its own GH in a natural, pulsatile pattern. The result: targeted visceral fat loss without the side effects of injecting growth hormone directly.Read article . PeRx publishes this page because the question people search most about tesamorelin is whether a symptom is normal, and the drug-label sites that rank for it never say what to do about one.

What Is Tesamorelin and How Does It Work?

Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH). Injected under the skin once a day, it signals the pituitary to release growth hormone in pulses, which in turn raises IGF-1, the growth factor that carries most of what growth hormone does. Egrifta SV and Egrifta WR are the two branded forms. Both are approved for a single indication: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The label is explicit that it is not a weight-loss drug, because its effect on body weight is neutral. What the trials measured Read nextTesamorelin Results: What the Trials Actually ShowedSearch for results on almost any peptide and you get mouse studies and marketing. Tesamorelin is the exception. The molecule went through two Phase 3 randomized trials with more than 800 patients, and the endpoint was not a survey or a scale. It was visceral fat measured by CT scan. This article walks through those numbers, the population they came from, what a realistic timeline looks like, and why the honest version of "tesamorelin before and after" involves a tape measure instead of a mirror.Read article was visceral fat on CT scans, not the scale, and its FDA approval status Read nextIs Tesamorelin FDA Approved? Yes, As EgriftaTesamorelin is the one growth hormone peptide in compounded use that holds a current FDA approval. The catch is what the approval covers: one indication, in one patient group, under a brand name most people have never heard of. Here is what the Egrifta approval does and does not mean for the compounded tesamorelin a clinic actually prescribes.Read article belongs to the brand, not to compounded versions.

The mechanism explains the risk profile. Anything that raises growth hormone and IGF-1 can cause fluid retention, joint pain, and changes in how the body handles glucose, and those three themes run through every section below. The same pattern applies to the other growth hormone peptides, which is why tesamorelin peptide side effects look familiar to anyone who has read about sermorelin Explore PeRxSermorelinThe Growth Hormone OptimizerView peptide or CJC-1295.

Tesamorelin Side Effects at a Glance: Frequency From Clinical Trials

The table below is Table 1 of the current Egrifta label, rebuilt with the placebo column kept in view. It combines the two 26-week placebo-controlled Phase 3 studies: 543 patients on tesamorelin and 263 on placebo. The label lists every reaction reported by at least 1% of treated patients and more often than on placebo. Percentages are whole numbers, exactly as the label prints them. The last column is our reading of when each one deserves a call.

Two things stand out. Joint pain, the most common entry, ran only two points above placebo, while injection-site reactions and muscle pain showed the clearest separation from it. Counted the broader way the label uses in its warnings, injection-site reactions of any kind reached 25% on tesamorelin against 14% on placebo. These were 26-week trials in people with HIV on antiretroviral therapy, so the rates in other groups may differ, and nobody has measured them. Older summaries, including the Drugs.com professional page, quote the 2010 label with decimals (13.3% for arthralgia, for example). The current label rounds the same data. For how this profile compares with other classes, see general peptide side effects Read nextPeptide Side Effects: Normal vs. Red Flag (2026)Most peptide side effects are mild local reactions that resolve in a day. A smaller set of systemic effects depends on the pathway the peptide acts on. And a third category, the one worth paying attention to, points to a problem with the product or the patient that should pause the protocol. Here is how to tell them apart.Read article .

Tesamorelin

A PeRx product. Tesamorelin at PeRx is prescribed by a licensed provider after an online health screening, compounded at a state-licensed 503A pharmacy, and shipped fully reconstituted and ready to use.

Renewals go through a check-in before each new prescription cycle. Compounded tesamorelin is not FDA-approved; the frequencies on this page come from the Egrifta trials.

PeRx product. Compounded tesamorelin is not FDA-approved.

View Tesamorelin

Common Side Effects of Tesamorelin

Grouped by what you would actually notice rather than by the order the label uses. The label adds one reassurance of its own: the fluid-related effects, which include most of this section, are described as either transient or resolving once treatment stops.

Injection-Site Reactions

The label lists redness, itching, pain, irritation and bruising at the tesamorelin injection site, and its trial footnote adds rash, hives, swelling and small bleeds. A mild reaction looks like a pink, itchy spot that fades within a day or two and moves with you as you rotate sites. The ones that need a call are different in kind: redness that keeps spreading, skin that feels hot, any drainage, a fever, or hives that appear away from the injection itself, which can be the first sign of an allergic reaction rather than a local one. Rotating across the abdomen is the label's own instruction for keeping these down, and our guide on where to inject tesamorelin Read nextWhere to Inject Tesamorelin: Sites and RotationTesamorelin is the rare peptide with FDA-approved labeling that tells you exactly where it goes: a subcutaneous injection into the abdomen, rotated. As of July 2026, that approved route is the anchor for how patients use it. Here is the practical site map, the rotation habit that keeps absorption consistent, and the technique details patients ask about after their first vial arrives.Read article covers the map.

Does Tesamorelin Cause Joint Pain? Joint Pain, Muscle Pain and Stiffness

Yes, though less dramatically than the raw number suggests. Arthralgia was reported by 13% of treated patients, the highest single entry, but 11% of the placebo group reported it too. Muscle pain (6% vs 2%), pain in an arm or leg (6% vs 5%) and stiffness (2% vs 0%) fill out the cluster. The label attributes all of it to the same cause, the growth hormone surge pulling fluid into tissue, and describes these effects as transient or as resolving once treatment stops. Rising joint pain that arrives together with numbness or tingling in the hands is the version to report, because that combination can mean the fluid is compressing the nerve at the wrist.

Water Retention and Swelling

Tesamorelin water retention shows up as swelling of the legs and feet (6% vs 2%) and, less often, swelling of a joint (1%). Growth hormone raises tissue turgor, so the places to watch are the hands and wrists, the ankles and feet, and the face on waking. Mild puffiness that eases through the day is the version most people describe in the first weeks. Call if swelling keeps increasing week on week, if one leg swells more than the other, or if it comes with hand tingling.

Tesamorelin and Headaches, Sleepiness and Sleep Changes

People ask why tesamorelin causes headaches, and the honest answer is that the current label does not list headache, dizziness, fatigue or insomnia among its trial reactions at all. Those symptoms come from patient reports and from older drug references, not from the label, so no mechanism can be claimed for them. Does tesamorelin make you sleepy? Some users describe deeper sleep in the first weeks, which fits a growth hormone pulse that normally peaks overnight, but the trials did not measure it. Night sweats were recorded in 1% of patients. A new headache that is persistent, or any change in vision alongside it, is worth a call rather than a wait.

Stomach, Skin and Mood Effects

Vomiting (3% vs 0%) and indigestion (2% vs 1%) are the digestive entries. Rash (4% vs 2%) and itching (2% vs 1%) cover the skin, with night sweats at 1%. The current label carries no mood entry; the 2010 version listed depression at 2% against 1.5% on placebo, and the newer table dropped it. Every item in this paragraph sits between 1% and 4% of treated patients, close to or at the placebo rate, so read them as possible rather than likely.

Serious Side Effects of Tesamorelin: When to Call Your Doctor

These are the tesamorelin risks the label singles out in its Warnings and Precautions. None is common. All of them need a clinician rather than a wait-and-see approach.

Allergic Reaction

Hypersensitivity reactions occurred in 4% of treated patients in the trials. The label names itching, redness, flushing, hives and rash, and its instruction is direct: seek prompt medical attention and stop the drug. Swelling of the face, lips, tongue or throat, trouble swallowing or breathing, or a racing heartbeat with any of these is an emergency, not a message to send later. One detail from the immunogenicity data explains the pattern: 85% of the patients who had a hypersensitivity reaction had developed antibodies to tesamorelin.

Blood Sugar Changes

Tesamorelin can cause glucose intolerance. In the trials, 5% of patients on the drug reached an HbA1c of 6.5% or higher by week 26, against 1% on placebo, a hazard ratio of 3.3. The label tells prescribers to evaluate glucose status before starting, to check it periodically, and to consider stopping if diabetes develops without a clear benefit. For anyone who already has diabetes, it adds a warning to watch for new or worsening retinopathy. Report any change in home glucose readings, and new thirst, frequent urination or blurred vision even if you have never been tested.

Nerve, Heart and Vision Symptoms

Carpal tunnel syndrome (1%), tingling (5%) and numbness (4%) are the nerve entries, and all three point to the fluid retention described above. Palpitations were recorded in 1%. Chest pain, a racing or irregular heartbeat, blurred vision, weakness or unsteadiness all need same-day medical attention. The label carries one more warning that rarely makes it into side-effect lists: pharmacologic growth hormone has been linked to increased mortality in critically ill patients after open heart surgery, abdominal surgery, major trauma or respiratory failure, so tesamorelin should be reconsidered in anyone who becomes acutely ill, and any hospital team should know you use it. Side effects can be reported to FDA MedWatch at 1-800-FDA-1088. Reactions to compounded tesamorelin are not captured in any trial, so the true rates outside the Egrifta studies are not known. Our guide to safety monitoring Read nextPeptide Safety Monitoring: Signals During TherapyThe most important safety tool on peptide therapy is your own attention. Most peptides are well tolerated, and the side effects people do notice are usually mild and easy to read once you know what is normal, what is worth mentioning, and what means stop and call your provider. This guide is about understanding your body on a peptide: the common symptoms, where your limits are, and when to reach out.Read article covers what to track at home.

Is Tesamorelin Safe Long Term? Cancer, IGF-1 and Antibodies

Does Tesamorelin Cause Cancer?

No trial has shown that it does, and no trial was long enough to rule it out. The label puts it this way: tesamorelin releases growth hormone, a known growth factor, and HIV-positive patients already carry an increased background risk of malignancy. It is contraindicated with any active cancer. A history of a non-malignant growth calls for careful evaluation first, a history of treated and stable cancer calls for weighing the benefit against reactivation, and any sign of recurrence means stopping. The label also states that long-term cardiovascular safety has not been established. Those are the tesamorelin long term side effects that remain open questions rather than measured ones.

IGF-1, Blood Sugar and Lab Monitoring

IGF-1 is the marker the label cares about. After 26 weeks, 47% of treated patients had IGF-1 more than two standard deviations above normal and 36% were above three, with the rise visible as early as week 13. At 52 weeks the figures were 34% and 23%. The label says the effects of prolonged elevation are unknown, asks prescribers to monitor IGF-1, and suggests stopping when it stays persistently high, especially if the fat response is not robust. Glucose or HbA1c sits alongside it. These checks are ordered by whoever manages your general health, so ask your own doctor about a baseline and a repeat; our guide to lab work before starting peptides Read nextLab Work Before Starting PeptidesThe honest answer to "what bloodwork do I need before peptides?" is: it depends on the peptide, and for many of them the answer is none. Some sites will tell you to buy a full baseline panel before anything, because they sell the panel. Here is the real picture, which peptides typically need no labs, where a provider may want to check IGF-1 and a metabolic panel, and why the decision belongs to the provider reviewing your history rather than to a checklist.Read article explains what each test shows.

Anti-Tesamorelin Antibodies

Half of treated patients developed IgG antibodies to tesamorelin by 26 weeks, 47% by 52 weeks, and about 60% of those cross-reacted with the body's own GHRH. Patients with and without antibodies had similar reductions in visceral fat and similar IGF-1 responses, so efficacy did not appear to suffer. Six months after stopping, 18% of the antibody-positive group still tested positive. What the label does not state is any safety consequence, and nobody has followed these patients for years. See long-term peptide safety Read nextAre Peptides Safe Long-Term? What the Data SaysMost safety questions about peptides assume the timeframe is one or two cycles. The harder question is what happens after a year, three years, or a decade. The honest answer is that peptides fall into three buckets: ones with multi-decade clinical data, ones with several years of safety record but limited long-term studies, and ones where the long-term picture is genuinely incomplete. Here is the bucket each peptide is in and what monitoring matters.Read article for how that gap compares across peptides.

Tesamorelin Contraindications: Who Should Not Use It

The label lists four tesamorelin contraindications: disruption of the hypothalamic-pituitary axis from pituitary surgery, a pituitary tumor, hypopituitarism, head irradiation or head trauma; active malignancy; known hypersensitivity to tesamorelin or any excipient in the product; and pregnancy.

Pregnancy, Breastfeeding and Children

Pregnancy is a contraindication, not a caution. The label's reasoning is that reducing visceral fat offers no benefit in pregnancy and could harm the fetus; in rats, doses two to four times the clinical exposure produced hydrocephaly in offspring. Anyone who becomes pregnant on tesamorelin should stop it. There are no data on tesamorelin in human milk, and the label advises against breastfeeding. Safety in children has not been established, and in those still growing the drug could accelerate linear growth. There is no information on use over age 65.

Existing Conditions to Raise With Your Provider

Beyond the four contraindications, the label asks for extra care with diabetes or prediabetes, diabetic retinopathy, existing swelling, carpal tunnel syndrome, any history of cancer, and glucocorticoid replacement for adrenal insufficiency, because growth hormone changes how cortisone and prednisone are activated. Mention any planned surgery as well, given the critical-illness warning. For tested athletes, one sentence settles it: tesamorelin is named on the 2026 WADA Prohibited List under growth hormone releasing factors (section S2.2.4) and is prohibited at all times. Our page on what providers review before prescribing peptides Read nextWhat Providers Review Before Prescribing PeptidesWhen your intake reaches a licensed provider, it is not a rubber stamp. There is a specific list they run down before any peptide is approved: the conditions that change whether a peptide is safe, the medication classes that have to be cross-checked, and the reasons an order gets sent back or declined. Here is that list, from the provider’s side of the screen.Read article lists what a screening asks.

Tesamorelin Side Effects in Men and Women

The label reports every frequency for the combined trial population and gives no breakdown by sex. We checked for one and there is none, so any page claiming that tesamorelin side effects differ for men or women is extrapolating. The only sex-specific statements in the label concern pregnancy and breastfeeding, covered above.

Tesamorelin Drug Interactions, Alcohol and Combinations

Share every prescription, over-the-counter medicine and supplement with the prescriber. Growth hormone can change how the liver clears drugs metabolized by CYP450 enzymes, so the label flags corticosteroids, sex steroids, anticonvulsants and cyclosporine; simvastatin and ritonavir were tested and their levels did not meaningfully change. People on cortisone acetate or prednisone replacement may need a dose adjustment. On tesamorelin and alcohol the label is silent, which is not the same as safe; see alcohol on peptides Read nextCan You Drink Alcohol on Peptides?For most peptides there is no absolute reason you cannot have a drink. The more useful question is what alcohol does to the results you are paying for. It tends to blunt the benefits and amplify the side effects, and how much depends on which peptide you are on. Here is the plain-language breakdown, category by category.Read article for the general reasoning. Tesamorelin ipamorelin side effects stack rather than cancel, because both raise growth hormone through different receptors, so swelling and joint aches are the overlap to expect. The tesamorelin and ipamorelin guide Read nextTesamorelin/Ipamorelin: Dosage and Cost (2026)Tesamorelin is the only FDA-approved GHRH analog, and the only GH peptide with Phase 3 trial data on visceral fat. This guide pairs it with Ipamorelin and focuses on what tesamorelin is actually proven to do: shrink deep abdominal fat, lower liver fat, and drive metabolic recomposition. If you want a general GH-support stack, the CJC-1295/Ipamorelin guide covers that. This page is about the FDA-approved, visceral-fat side of the GH peptide world.Read article covers that pairing, and tesamorelin vs CJC-1295 Read nextTesamorelin vs CJC-1295/Ipamorelin 2026: FDA vs DualTesamorelin is the only FDA-approved growth hormone peptide. CJC-1295/Ipamorelin is the most popular compounded GH stack. Both stimulate your pituitary to produce growth hormone, but they do it differently and they have very different regulatory histories. Here is the honest comparison to help you choose.Read article compares the two GHRH analogs.

How to Reduce Tesamorelin Injection Side Effects

Injection Technique and Site Rotation

The label's own list is short. Inject into the abdomen and rotate to a different area of it each day. Skip scar tissue, bruises, hard lumps and the navel. Use a new needle and syringe every time. Check the vial before each dose and do not use it if the solution is cloudy, discolored or has particles in it. Let the alcohol swab dry before the needle goes in, since wet alcohol stings and is one reason tesamorelin burns on injection. Inject slowly, and do not rub the site afterward. The full technique, including angle and pinch, is in how to inject peptides Read nextHow to Inject Peptides: Subcutaneous GuideA clear, practical walkthrough of subcutaneous peptide injections, from supply setup to sharps disposal. Written for patients new to self-injection with ready-to-use PeRx vials.Read article .

Dose, Missed Doses and Storage

For reference only, the labeled doses are 1.28 mg of Egrifta WR or 1.4 mg of Egrifta SV once daily; the prescribing provider sets the dose for any compounded product, and the tesamorelin dosage chart Read nextTesamorelin Dosage Chart: Units, Timing, CostTesamorelin dosing numbers found online disagree with each other for a reason: three different Egrifta labels say 2 mg, 1.4 mg, and 1.28 mg, and none of them describe a compounded vial. This page sorts out the three labels, converts milligrams to insulin-syringe units at the 3 mg/mL concentration PeRx ships, and covers timing, cycle length, missed doses, and what a month costs, as of August 31, 2026.Read article converts the three labels into syringe units. The label gives no missed-dose rule, so follow the instruction that came with your prescription and never inject a double dose to catch up. Storage differs by product: the Egrifta kits are room-temperature products, while PeRx ships tesamorelin fully reconstituted and ready to use, stored refrigerated at 36 to 46 degrees Fahrenheit and never frozen.

Tesamorelin at PeRx: Prescription and Renewal Check-Ins

Egrifta is FDA-approved for HIV-associated lipodystrophy. Compounded tesamorelin, including what PeRx dispenses, is not FDA-approved, and no compounded peptide is. Through PeRx a licensed provider reviews your health screening and, if appropriate, prescribes tesamorelin, which is compounded at a state-licensed 503A pharmacy and shipped overnight. Each renewal goes through a check-in before the next prescription cycle opens. The tesamorelin side effects on this page are the ones to raise in that check-in, or sooner through your care team if any of the serious ones appear. Related options are the Tesamorelin/Ipamorelin Explore PeRxTesamorelin/IpamorelinVisceral Fat & Lean Muscle GH ComboView peptide combination and the wider growth hormone peptides range, and how PeRx tests its peptides explains the batch testing behind every vial.

Frequently Asked Questions About Tesamorelin

References

Every frequency on this page comes from the current prescribing information, retrieved from DailyMed in October 2026. Mayo Clinic and Drugs.com are useful secondary pages; where they differ from the figures here, they are quoting the 2010 label.

EGRIFTA WR (tesamorelin for injection) prescribing information. Theratechnologies Inc., revised March 2025. Sections 1, 2, 4, 5, 6.1, 7, 8, 12.6 and 16. DailyMed set ID 839334d3-8c1d-4c26-9036-2ab524a6ea75. View study

EGRIFTA SV (tesamorelin for injection) prescribing information. Theratechnologies Inc., revised February 2024. DailyMed set ID 3d783378-b02d-4f19-99dd-0fc91a042224. View study

U.S. Food and Drug Administration. Drugs@FDA: BLA 022505, EGRIFTA (tesamorelin). Approval history and labels, original approval November 2010; EGRIFTA WR supplement approved March 25, 2025. View study

World Anti-Doping Agency. The 2026 Prohibited List, in force January 1, 2026. Section S2.2.4, growth hormone releasing factors, names tesamorelin explicitly. View study